Moderna MRNA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$1.34B-38.3% | -$826M+26.3% | -$200M-1,638% | -$825M+35.5% | -$971M+17.4% | ||
| $59M+51.3% | $67M+11.7% | $52M0.0% | $57M+39.0% | $39M+8.3% | ||
| $104M-9.6% | $113M+8.7% | $125M+11.6% | $130M+16.1% | $115M+13.9% | ||
| -$114M+59.3% | -$859M+28.8% | $1.01B-27.7% | -$30M— | -$280M+62.9% | ||
| -$6M-175% | —— | $91M+727% | $114M+9.6% | $8M-91.4% | ||
| -$120M+23.1% | —— | —— | -$47M— | -$156M+48.5% | ||
| $464M+222% | —— | —— | -$14M+78.8% | -$381M+4.3% | ||
| -$54M-17.4% | -$237M+18.8% | -$66M-144% | $196M— | -$46M-1,433% | ||
| $26M-21.2% | —— | -$112M-2,900% | -$58M+68.8% | $33M-72.3% | ||
| -$6M-200% | -$27M+50.0% | -$14M— | -$34M-750% | -$2M+33.3% | ||
| $5M+117% | —— | $40M+112% | $97M-45.8% | -$29M+12.1% | ||
| -$7M-40.0% | -$6M— | -$5M-163% | -$5M-116% | -$5M+16.7% | ||
| -$2M+75.0% | -$3M+66.7% | —— | —— | -$8M+38.5% | ||
| -$630M+39.2% | —— | -$847M+45.9% | -$919M+27.9% | -$1.04B-4.9% | ||
| $62M-47.0% | $39M-92.5% | $33M-78.1% | $3M-98.4% | $117M-40.3% | ||
| $1.35B-23.6% | $1.55B-18.1% | $1.16B-7.1% | $1.3B+53.1% | $1.76B-30.7% | ||
| $602M-12.5% | $609M-36.4% | $685M-32.2% | $371M-48.0% | $688M-46.5% | ||
| $0-100% | —— | —— | —— | $10M— | ||
| -$76M-110% | $0— | $700M-2.9% | $564M-65.8% | $730M+519% | ||
| —— | $150M— | $150M— | $150M— | $150M— | ||
| $19M+533% | $16M+45.5% | $2M-75.0% | $14M-56.3% | $3M-80.0% | ||
| $2M+100% | —— | —— | —— | $1M— | ||
| —— | $5.5M— | $5.5M— | $5.5M— | $5.5M— | ||
| $17M+325% | $581M— | $0-100% | $9M-73.5% | $4M-71.4% | ||
| $1M— | $0+100% | $1M0.0% | $1M— | $0— | ||
| -$688M-127% | $1.46B— | -$147M+82.4% | -$345M— | -$303M+64.6% | ||
| —— | $2.5M-58.3% | $2.5M-58.3% | $2.5M-58.3% | $2.5M-58.3% | ||
| —— | $6.5M-86.8% | $6.5M-86.8% | $6.5M-86.8% | $6.5M-86.8% | ||
| -$2M+75.0% | -$3M+66.7% | —— | —— | -$8M+38.5% | ||
| -$7M-40.0% | -$6M— | -$5M-163% | -$5M-116% | -$5M+16.7% | ||
| -$54M-17.4% | -$237M+18.8% | -$66M-144% | $196M— | -$46M-1,433% | ||
| -$11M-22.2% | -$10M— | -$9M-1,000% | -$10M-113% | -$9M+43.8% | ||
| $11M-42.1% | $13M-31.6% | $17M-19.0% | $18M-35.7% | $19M-29.6% | ||
| $59M+51.3% | $67M+11.7% | $52M0.0% | $57M+39.0% | $39M+8.3% | ||
| -$6M-200% | -$27M+50.0% | -$14M— | -$34M-750% | -$2M+33.3% | ||
| $0-100% | —— | —— | —— | $10M— | ||
| $732M-62.1% | $929M+1.6% | $1.21B+8.8% | $1.49B-24.0% | $1.93B+22.9% | ||
| $602M-12.5% | $609M-36.4% | $685M-32.2% | $371M-48.0% | $688M-46.5% | ||
| $0+100% | $12M-14.3% | $3M+200% | $5M+350% | -$2M-300% | ||
| —— | $5.5M— | $5.5M— | $5.5M— | $5.5M— | ||
| $19M+533% | $16M+45.5% | $2M-75.0% | $14M-56.3% | $3M-80.0% | ||
| $35M-30.0% | $41M+116% | —— | —— | $50M-45.1% | ||
| $74M— | —— | —— | —— | $0— | ||
| —— | $6.5M-86.8% | $6.5M-86.8% | $6.5M-86.8% | $6.5M-86.8% | ||
| -$692M+40.0% | —— | -$880M+48.7% | -$922M+36.7% | -$1.15B+2.6% | ||
| -$692M+40.0% | —— | -$880M+48.7% | -$922M+36.7% | -$1.15B+2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Moderna generate?
- Moderna (MRNA) generated -$3.4B in operating cash flow over the trailing twelve months.
- What is Moderna's free cash flow?
- After $137.0M of capital expenditures, Moderna's free cash flow was -$3.6B over the trailing twelve months, up 16.3% year over year.
- Where does Moderna's cash flow data come from?
- Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
